Embecta (EMBC) Expected to Announce Earnings on Thursday

Embecta (NASDAQ:EMBC - Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 6th. Analysts expect Embecta to post earnings of $0.45 per share and revenue of $256.08 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Parties interested in participating in the company's conference call can do so using this link.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings data on Tuesday, November 26th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.05. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. The business had revenue of $286.10 million during the quarter, compared to analysts' expectations of $276.97 million. During the same quarter in the previous year, the firm earned $0.59 EPS. The firm's revenue was up 1.5% compared to the same quarter last year. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Down 0.2 %

Shares of EMBC stock traded down $0.04 during trading hours on Thursday, reaching $18.36. 172,497 shares of the company's stock were exchanged, compared to its average volume of 374,800. The business has a fifty day moving average price of $19.52 and a 200-day moving average price of $16.35. The stock has a market capitalization of $1.07 billion, a P/E ratio of 13.60, a P/E/G ratio of 1.02 and a beta of 1.23. Embecta has a fifty-two week low of $9.93 and a fifty-two week high of $21.48.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th were given a $0.15 dividend. The ex-dividend date was Friday, December 6th. This represents a $0.60 annualized dividend and a yield of 3.27%. Embecta's dividend payout ratio is 44.44%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on EMBC. BTIG Research upgraded Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price target on the stock in a research note on Wednesday, November 27th. Morgan Stanley upgraded shares of Embecta from an "underweight" rating to an "equal weight" rating and boosted their price objective for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.